A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT)

Trial Profile

A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN SC IN COMBINATION WITH PERJETA AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; Registrational
  • Acronyms MetaPHER
  • Sponsors Roche
  • Most Recent Events

    • 12 Apr 2017 Planned End Date changed from 1 Feb 2019 to 19 Mar 2019.
    • 12 Apr 2017 Planned primary completion date changed from 1 Feb 2019 to 19 Mar 2019.
    • 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top